Translational-Research
Translational-Research funding pages collect matching grants, scholarships, benefits, fellowships, and other programs from the FindMyMoney.App directory. Use this page to compare current opportunities, then verify deadlines and eligibility on the official source before applying.
March of Dimes Discovery Research Grants 2027: $200,000 Over Two Years for Established Scientists Working on Spontaneous Preterm Birth and Cardiovascular Conditions in Pregnancy — Portal Closes 8 September 2026
March of Dimes is accepting applications for its top-tier Discovery Research Grants, worth $200,000 over two years inclusive of 10% indirect costs, for translational research in spontaneous preterm birth or pregnancy-related cardiovascular conditions; the portal opened 8 June 2026 and closes 8 September 2026, with awards running 1 February 2027 to 31 January 2029.
NIH Opportunities for Collaborative Research at the NIH Clinical Center (U01 Clinical Trial Optional)
This NIH PAR-26-116 cooperative agreement supports translational research led by extramural investigators that uses NIH Clinical Center infrastructure through a planned collaboration with NIH intramural investigators.
NIH Quantum Sensing Technology Challenge
Historical reference for the completed NIH prize competition led by NCATS to adapt existing quantum-enabled sensing technologies for biomedical and clinical use cases.
PAR-27-072: Bioengineering Research Grants (R01) for Translational Biomedical Engineering
NIH Bioengineering Research Grants support R01 applications that integrate engineering, quantitative, and physical science approaches to create or adapt technologies and methods that can be translated into biomedical solutions, with recurring deadlines across 2026 and 2027 and open intake.
RFA-DA-26-034: Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on the Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic Opioids
NIH Trans-NIH RFA supports basic and applied research on acute exposure effects and delayed effects of ultra-potent synthetic opioids, with recurring R01 due dates in 2026 and 2027.
RFA-DE-27-002: Accelerating Product Excellence in Innovation and for Clinical Adoption (APEx) (U24 Clinical Trial Not Allowed)
NIH Notice of Funding Opportunity for one U24 Resource Center and associated Interdisciplinary Translational Projects to advance tissue engineering and regenerative medicine products through preclinical development toward clinical adoption.
RFA-HL-26-017: NIH Catalyze Product Definition for Small Molecules and Biologics (R61/R33)
NIH's RFA-HL-26-017 supports early-stage translational projects that generate and validate therapeutic candidates for HLBS diseases through a phased R61/R33 development pathway.
RFA-HL-26-019: Catalyze Product Definition - Medical Device Prototype Design/Testing and Disease Target Identification and Assay Development (R61/R33; Clinical Trial Not Allowed)
NIH NHLBI Catalyze Product Definition NOFO for early-stage device, diagnostic, and research-tool development in heart, lung, blood, and sleep diseases. The next new-application due date is October 21, 2026.
UKRI Translation: MRC Impact Acceleration Award 2026: £50,000 to £300,000 for One High-Risk Development Step Toward a New Medicine, Device, or Diagnostic — Applications Close 11 November 2026
The Medical Research Council funds a single, tightly scoped package of translational development work — £50,000 to £300,000 at 80% full economic cost, over six to 18 months — to generate the critical data that decides whether a medical product idea progresses or stops.